Fig. 2: FSP1 promotes GC chemoresistance by suppressing ferroptosis.

a Immunoblot of FSP1 in AGS cisplatin sensitive (S) and resistant (R) cells. b Percentage of C11-BODIPY-positive cells in the indicated AGS cells with/without 24-h cisplatin (2 μM) treatment. c Immunoblot of FSP1 in AGS-R cells stably expressing control or two independent FSP1 sgRNAs. d Percentage of C11-BODIPY-positive cells in cells from (c) with/without 24-h cisplatin (2 μM) treatment. e Survival fraction of cells from (c) exposed to cisplatin at the indicated doses for 2 weeks. f Immunoblot of FSP1 in AGS-R cells stably expressing the indicated vectors. g Percentage of C11-BODIPY-positive cells in cells from (f) with/without 24-h cisplatin (2 μM) treatment. h Survival fraction of cells from (f) exposed to cisplatin at the indicated doses for 2 weeks. i Survival fraction of control or FSP1-KO AGS-R cells exposed to cisplatin at the indicated dose combining with/without the indicated reagents for 2 weeks. j Growth curves of the AGS-R xenograft tumor models with the indicated treatment. k Quantification of the weight of the tumors in different groups of the xenograft tumor models. Experiment was repeated 3 times, and representative blots are presented in (a, c, f). Data shown represent mean ± SD from three independent experiments (b, d, e, g–i), or from one representative experiment of 5 mice per group in (j, k). P values are determined by unpaired 2-sided Student’s t test in (b), 1-way ANOVA in (d, g, k), or 2-way ANOVA in (e, h–j). The survival fraction was calculated as the ratio of colony-forming cells with the indicated treatment to those in the untreated control group. NS, not significant. Source data are provided as Source Data file.